Bank Of Montreal Bio Atla, Inc. Transaction History

Bank Of Montreal

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$0.59 - $2.37 $308,128 - $1.24 Million	-522,252 Reduced 87.67%	73,484 $43,000
Q3 2024 Nov 13, 2024	BUY	$1.17 - $2.05 $224,099 - $392,652	191,538 Added 47.39%	595,736 $1.05 Million
Q2 2024 Aug 14, 2024	BUY	$1.37 - $3.92 $196,623 - $562,602	143,521 Added 55.06%	404,198 $553,000
Q1 2024 May 13, 2024	SELL	$1.88 - $3.46 $75,092 - $138,202	-39,943 Reduced 13.29%	260,677 $896,000
Q4 2023 Feb 08, 2024	BUY	$1.27 - $3.18 $103,661 - $259,561	81,623 Added 37.27%	300,620 $739,000
Q3 2023 Nov 01, 2023	BUY	$1.7 - $3.07 $344,962 - $622,961	202,919 Added 1262.09%	218,997 $372,000
Q2 2023 Aug 02, 2023	BUY	$2.83 - $3.87 $45,500 - $62,221	16,078 New	16,078 $48,000
Q1 2023 Jun 13, 2024	SELL	$2.3 - $8.25 $574,080 - $2.06 Million	-249,600 Reduced 95.75%	11,077 $29,000

13.4M

20.7K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $13.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.